JUNS
Jupiter Neurosciences Inc
$
1.330
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.360
Open
1.340
VWAP
1.35
Vol
90.55K
Mkt Cap
45.79M
Low
1.3083
Amount
122.00K
EV/EBITDA(TTM)
--
Total Shares
34.43M
EV
44.06M
EV/OCF(TTM)
--
P/S(TTM)
--
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Show More
1 Analyst Rating
Wall Street analysts forecast JUNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JUNS is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.330
Low
30.00
Averages
30.00
High
30.00
Current: 1.330
Low
30.00
Averages
30.00
High
30.00
Greenridge
William Gregozeski
Buy
downgrade
$30 -> $25
2025-11-05
New
Reason
Greenridge
William Gregozeski
Price Target
$30 -> $25
2025-11-05
New
downgrade
Buy
Reason
Greenridge analyst William Gregozeski lowered the firm's price target on Jupiter Neurosciences to $25 from $30 and keeps a Buy rating on the shares after the company announced last week that it entered into a $20M Standby Equity Purchase Agreement with Yorkville Advisors. The firm added in the cash and dilutive impact from the initial $6M advance and is assuming the notes are repaid with stock at $1.50 per share, the analyst noted.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Jupiter Neurosciences Inc (JUNS.O) is -5.54, compared to its 5-year average forward P/E of -5.76. For a more detailed relative valuation and DCF analysis to assess Jupiter Neurosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.76
Current PE
-5.54
Overvalued PE
-2.99
Undervalued PE
-8.53
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
49.95
Current PS
1.33
Overvalued PS
92.94
Undervalued PS
6.97
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+306.56%
-2.26M
Operating Profit
FY2025Q2
YoY :
-819.51%
-2.25M
Net Income after Tax
FY2025Q2
YoY :
-800.00%
-0.07
EPS - Diluted
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
JUNS News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
08:32:30
Jupiter Secures FDA Approval for IND Application to Start Phase 2 Trial
2025-10-27 (ET)
2025-10-27
08:36:47
Jupiter Neurosciences secures financing agreements totaling up to $20 million
2025-09-15 (ET)
2025-09-15
08:18:04
Jupiter Neurosciences Appoints Biohacker Jean Fallacara as Ambassador for Nugevia
Sign Up For More Events
Sign Up For More Events
News
9.0
11-05NewsfilterJupiter Neurosciences Obtains FDA Approval for IND Application to Start Phase 2a Clinical Trial of JOTROL™ for Parkinson's Disease
7.5
09-15NewsfilterJupiter Neurosciences Appoints Innovative Entrepreneur and Biohacker Jean Fallacara as the Third Ambassador for Nugevia™ Brand
5.0
08-11NewsfilterJupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
Sign Up For More News
People Also Watch
AAPL
Apple Inc
268.470
USD
-0.48%
NVDA
NVIDIA Corp
188.150
USD
+0.04%
MSFT
Microsoft Corp
496.820
USD
-0.06%
META
Meta Platforms Inc
621.710
USD
+0.45%
TSLA
Tesla Inc
429.520
USD
-3.68%
AMZN
Amazon.com Inc
244.410
USD
+0.56%
XOM
Exxon Mobil Corp
117.220
USD
+2.38%
WMT
Walmart Inc
102.590
USD
+0.89%
ORCL
Oracle Corp
239.260
USD
-1.86%
AVGO
Broadcom Inc
349.430
USD
-1.73%
FAQ
What is Jupiter Neurosciences Inc (JUNS) stock price today?
The current price of JUNS is 1.33 USD — it has decreased -2.21 % in the last trading day.
What is Jupiter Neurosciences Inc (JUNS)'s business?
What is the price predicton of JUNS Stock?
What is Jupiter Neurosciences Inc (JUNS)'s revenue for the last quarter?
What is Jupiter Neurosciences Inc (JUNS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Jupiter Neurosciences Inc (JUNS)'s fundamentals?
How many employees does Jupiter Neurosciences Inc (JUNS). have?